PTX-COVID19-B

PTX-COVID19-B is a mRNA vaccine candidate developed by Providence Therapeutics and its partner company, Northern RNA, for the prevention of COVID-19. The vaccine is currently in the clinical trial phase.

Etymology

The name "PTX-COVID19-B" is derived from the initials of the company that developed it, Providence Therapeutics (PT), and the disease it is designed to prevent, COVID-19. The "B" in the name signifies that it is a variant of the original vaccine.

Development

Providence Therapeutics and Northern RNA began the development of PTX-COVID19-B in early 2020, shortly after the SARS-CoV-2 virus was identified. The vaccine is based on mRNA technology, similar to the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.

Clinical Trials

The Phase 1 clinical trial for PTX-COVID19-B began in January 2021, with 60 participants aged 18-64. The trial aims to evaluate the safety, tolerability, and immunogenicity of the vaccine. The results of the Phase 1 trial are expected to inform the design of subsequent Phase 2 and 3 trials.

Mechanism

PTX-COVID19-B is an mRNA vaccine, which works by introducing a small piece of the SARS-CoV-2 virus's mRNA into the body. This mRNA instructs cells to produce a harmless piece of the virus, triggering an immune response.

Related Terms

• mRNA vaccine
• Providence Therapeutics
• Northern RNA
• COVID-19
• SARS-CoV-2
• Pfizer-BioNTech COVID-19 vaccine
• Moderna COVID-19 vaccine